J&J's run to record highs hasn't reached the finish line yet. Here are the key drivers
Johnson & Johnson’s Stock Continues to Climb
Johnson & Johnson’s shares have surged to fresh record levels and analysts say the upside is far from exhausted. The stock closed above $275 on Tuesday, marking a seventh consecutive day of gains and outpacing the broader market, which is up about 12% year‑to‑date. J&J itself has risen roughly 33% since the start of the year, making it one of the standout performers in the S&P 500.
Growth Prospects and Earnings Quality
UBS lifted its target price for the healthcare conglomerate to $320 a share, up from $280, citing three core reasons. First, the firm expects revenue growth to accelerate from a historical 4%‑6% compound annual growth rate to an 8%‑plus trajectory for the remainder of the decade. Second, analysts foresee a multiple expansion as the company re‑positions itself as a growth‑oriented stock and earns a higher valuation on Wall Street. Third, a shift toward higher‑margin products should improve earnings quality, reinforcing the bullish outlook.
Defensive Stocks Rally
Defensive equities have been buoyed as the artificial‑intelligence trade encounters volatility, and J&J has benefited from that broader rotation. The company’s strong balance sheet and diversified product mix have helped it stand out among peers, reinforcing its appeal to investors seeking stability amid market turbulence.
Oncology Leadership
The oncology segment remains a key engine of revenue. Darzalex, J&J’s multiple‑myeloma therapy, generated more than $4 billion in sales during the second quarter, posting an 18% increase from the prior period. The drug retains U.S. patent protection until 2029, and UBS expects a gradual erosion rather than a sharp cliff, allowing Darzalex to stay a meaningful revenue source well into the next decade. Analysts project that market penetration could near 80%, supporting peak annual sales in the $22 billion to $23 billion range, and they continue to label the treatment the “dominant standard of care” for first‑line multiple‑myeloma therapy.
Immunology and New Launches
J&J’s immunology franchise also contributes to the growth narrative. Tremfya, an injectable IL‑23 inhibitor, has been highlighted as the fastest‑growing advanced therapy for both Crohn’s disease and ulcerative colitis, delivering a 71% sales jump in the most recent quarter. The newer oral IL‑23 inhibitor Icotyde, approved by the FDA in mid‑March for plaque psoriasis, is projected by UBS to have a peak‑sales potential exceeding $10 billion, positioning it as a future blockbuster.
Robotic Surgery Platform
The recently authorized Ottava robotic surgery system adds another growth vector. While adoption of complex surgical robots typically unfolds over several years, UBS believes that if Ottava captures a meaningful share of the market faster than expected, it could lift J&J’s surgery revenues beyond current forecasts. The platform will compete directly with Intuitive Surgical’s established da Vinci system, a dynamic that may shape market share outcomes in the coming years.
Analyst Confidence and Investor Outlook
UBS characterizes Johnson & Johnson as one of the “cleanest stories in large‑cap pharma,” noting the absence of imminent patent cliffs or binary risks that often unsettle pharmaceutical stocks. Jim Cramer echoed that sentiment on his CNBC program, describing the drug business as having “taken on a momentum of its own.” Cramer’s charitable trust holds a sizable position in J&J, and subscribers to his investing club receive trade alerts before he executes any moves, offering additional insight into his timing strategy.
With a robust pipeline, solid earnings prospects, and a defensive market backdrop, Johnson & Johnson appears poised to extend its rally well beyond the current record highs.
Source: CNBC · 2026-09-02